Generate Biomedicines (NASDAQ:GENB) Stock Price Down 9.7% – Time to Sell?

Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report)’s stock price fell 9.7% on Monday. The stock traded as low as $11.02 and last traded at $10.9040. 255,397 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 861,277 shares. The stock had previously closed at $12.07.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GENB. Weiss Ratings raised shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 25th. Wall Street Zen downgraded shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Generate Biomedicines in a research report on Friday, October 30th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.40.

View Our Latest Stock Report on GENB

Generate Biomedicines Trading Down 11.6%

The business’s 50-day simple moving average is $14.35 and its two-hundred day simple moving average is $14.11. The firm has a market capitalization of $1.37 billion and a price-to-earnings ratio of -6.71. The company has a quick ratio of 5.01, a current ratio of 5.01 and a debt-to-equity ratio of 0.02.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.18). The company had revenue of $4.22 million during the quarter. Generate Biomedicines had a negative return on equity of 151.21% and a negative net margin of 1,289.97%. Equities analysts forecast that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Trading of Generate Biomedicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GENB. Magnus Financial Group LLC boosted its position in shares of Generate Biomedicines by 39.4% during the third quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock worth $327,000 after buying an additional 6,150 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Generate Biomedicines in the second quarter valued at $196,000. AXQ Capital LP purchased a new stake in shares of Generate Biomedicines in the 2nd quarter valued at $218,000. Summa Corp. purchased a new stake in shares of Generate Biomedicines in the 3rd quarter valued at $250,000. Finally, State Street Corp lifted its stake in Generate Biomedicines by 3.8% during the 3rd quarter. State Street Corp now owns 546,337 shares of the company’s stock worth $8,206,000 after acquiring an additional 19,772 shares in the last quarter.

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

Featured Stories

Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.